{"id":61809,"date":"2025-09-03T07:06:43","date_gmt":"2025-09-03T05:06:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dynamic-growth-leads-c2n-diagnostics-to-expand-st-louis-headquarters-to-meet-global-need-for-answers-to-alzheimers-disease\/"},"modified":"2025-09-03T07:06:43","modified_gmt":"2025-09-03T05:06:43","slug":"dynamic-growth-leads-c2n-diagnostics-to-expand-st-louis-headquarters-to-meet-global-need-for-answers-to-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dynamic-growth-leads-c2n-diagnostics-to-expand-st-louis-headquarters-to-meet-global-need-for-answers-to-alzheimers-disease\/","title":{"rendered":"Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer\u2019s Disease"},"content":{"rendered":"
\n

ST. LOUIS–(BUSINESS WIRE)–#Alzheimers<\/a>—C2N Diagnostics, LLC<\/a> (\u201cC2N\u201d), a specialty diagnostics company with a vision to bring Clarity Through Innovation\u00ae, is proud to announce that its early achievements while based in St. Louis are allowing it to triple the size of its operations in its hometown.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nC2N, a leader in advanced brain health diagnostics, will relocate its headquarters and expand its federally regulated CAP accredited-CLIA certified lab<\/a> operation to 4140 Forest Park Ave. at Catalyst, Powered by WashU, in the Cortex Innovation District in Midtown. Washington University is redeveloping the former Goodwill Industries International site. The new lab will leverage the latest advancements in bioautomation and high-resolution, high-throughput proteomic testing. Altogether, C2N will occupy 82,451 new square feet at Catalyst, filling the first three floors. C2N expects to begin the move in late 2026.<\/p>\n

\nIn addition to the new headquarters, C2N will maintain its existing ISO 13485:2016 compliant lab facility and turn it into a center dedicated to providing cutting-edge multi-omic solutions and advanced analytical platforms to drive innovation across its biopharmaceutical research services and medtech business units, and international collaborative research initiatives.<\/p>\n

\nDr. Joel Braunstein, CEO of C2N, said, \u201cThis news is a testament to the enthusiastic backing we\u2019ve received in St. Louis, the extremely talented team members we employ, and the health care professionals who\u2019ve embraced our technology and premium quality testing services. We\u2019re especially excited to be growing in the Cortex Innovation District, where we started and where we feel we exemplify its passion for providing the resources needed to shape the future.\u201d<\/p>\n

\n\u201cThe ongoing success of C2N Diagnostics in St. Louis is proof that Missouri is leading the way in groundbreaking medical research,\u201d said Governor Mike Kehoe. \u201cTheir partnership with Washington University demonstrates the powerful impact of science and entrepreneurship happening right here in Missouri.\u201d<\/p>\n

\nC2N is best known for commercializing the first clinical blood test for Alzheimer\u2019s disease and more recently for its highly accurate PrecivityAD2\u2122 blood test<\/a>, which helps health care professionals in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s disease, and inform medical management and treatment decisions.<\/p>\n

\nThe company said the following are fueling its pacesetting role:<\/p>\n